Media Articles Related to Folotyn (Pralatrexate)
In drug-resistant non-Hodgkin lymphomas, 'survival' protein may be a target
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.01.14]
Melbourne researchers have discovered that targeting a cell 'survival' protein could help treat some lymphomas, including those cancers with genetic defects that make them resistant to many existing...
Added benefit of idelalisib for follicular lymphoma or chronic lymphocytic leukaemia is not proven
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.01.12]
Idelalisib (trade name Zydelig) has been available since September 2014 for patients with follicular lymphoma or chronic lymphocytic leukaemia (CLL).
Mutations prevent programmed cell death in lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2014.12.30]
Programmed cell death is a mechanism that causes defective and potentially harmful cells to destroy themselves.
Janssen launches Imbruvica, first-in-class treatment for patients with Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL) in UK
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2014.12.22]
Imbruvica® (ibrutinib), an oral, once-daily, first- in-class treatment, has been launched in the UK.
Study compares effectiveness of antiviral drugs to prevent hepatitis B virus-related hepatitis among patients receiving chemotherapy for lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2014.12.17]
Among patients with lymphoma undergoing a certain type of chemotherapy, receiving the antiviral drug entecavir resulted in a lower incidence of hepatitis B virus (HBV)-related hepatitis and HBV...
Published Studies Related to Folotyn (Pralatrexate)
Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial. [2011.11]
INTRODUCTION: Pralatrexate is an antifolate designed for preferential tumor cell uptake and accumulation and received accelerated Food and Drug Administration approval in relapsed/refractory peripheral T-cell lymphoma. Pralatrexate 135 to 150 mg/m(2) every 2 weeks without vitamin supplementation was active in non-small cell lung cancer (NSCLC) although mucositis was dose limiting. This phase 1 study evaluated the safety of higher pralatrexate doses with vitamin supplementation to minimize toxicities... CONCLUSIONS: Pralatrexate with vitamin supplementation was safely administered to patients with previously treated NSCLC, and durable responses were observed. The recommended starting dose for phase 2 is 190 mg/m(2). A similar safety profile was observed in patients treated at 230 mg/m(2), although a higher serious AE rate was evident. Mucositis remains the dose-limiting toxicity of pralatrexate, and this study failed to demonstrate that vitamin supplementation prevents mucositis and failed to identify clinical predictors of mucositis. Individualized dose-modification strategies and prospective mucositis management will be necessary in future trials.
Pralatrexate: A novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses. [2011.09.26]
CONCLUSION: PDX provides clinical benefit to patients with relapsed or refractory PTCL with durable complete and partial responses in patients who had not responded to multiple prior treatment regimens.
Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. [2011.09]
INTRODUCTION: Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of T-cell neoplasms. Most patients with PTCL have a poor outcome with conventional therapies and are not cured without stem-cell transplantation... The most frequent adverse events in these trials were mucositis, reversible thrombocytopenia and fatigue.
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. [2011.03.20]
PURPOSE: Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's lymphoma with no accepted standard of care. This study evaluated the efficacy and tolerability of pralatrexate, a novel antifolate with promising activity... CONCLUSION: To our knowledge, PROPEL (Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma) is the largest prospective study conducted in patients with relapsed or refractory PTCL. Pralatrexate induced durable responses in relapsed or refractory PTCL irrespective of age, histologic subtypes, amount of prior therapy, prior methotrexate, and prior autologous stem-cell transplant. These data formed the basis for the US Food and Drug Administration approval of pralatrexate, the first drug approved for this disease.
Single agent and combination studies of pralatrexate and molecular correlates of sensitivity. [2011.01.18]
BACKGROUND: Pralatrexate is a dihydrofolate reductase (DHFR) inhibitor with high affinity for reduced folate carrier 1 (RFC-1) and folylpolyglutamate synthetase (FPGS), resulting in extensive internalization and accumulation in tumour cells. Pralatrexate is approved in the US for the treatment of relapsed or refractory peripheral T-cell lymphoma and is being investigated in various malignancies. Here, we evaluated molecular correlates of sensitivity to pralatrexate and explored combinations with a variety of anticancer agents... CONCLUSION: Pralatrexate was more potent than methotrexate in a panel of solid tumour lines. Our findings support the further clinical development of pralatrexate in combination with certain cytotoxics and targeted therapies, and suggest that RFC-1, FPGS and DHFR may be potential biomarkers of outcome.
Clinical Trials Related to Folotyn (Pralatrexate)
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies [Recruiting]
This study is for patients with lymphoproliferative malignancies that have progressed after
receiving a previous treatment (relapsed) or are no longer responding to treatment
(refractory). To be in this study, patients must have certain types of Hodgkin's lymphoma
(HL), peripheral T-cell lymphoma (PTCL), or B-cell lymphoma, including Waldenstrom's
This study is being done to find doses of the combination of pralatrexate and gemcitabine
with vitamin B12 and folic acid that can be safely given to patients with these types of
lymphoma and explore the effectiveness of the treatment.
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer [Recruiting]
RATIONALE: Pralatrexate may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving pralatrexate and oxaliplatin together may kill more tumor cells.
PURPOSE: This phase II trial is studying how well pralatrexate and oxaliplatin work in
treating patients with unresectable or metastatic esophageal, stomach, or gastroesophageal
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) [Recruiting]
The purpose of this study is to find out if the experimental drug pralatrexate with the
vitamins folic acid and vitamin B12 might be an effective treatment for head and neck
cancer. The reason we are doing this study is because another drug called methotrexate has
been used for a long time to treat head and neck cancer patients. Pralatrexate was designed
by scientists to be a new drug that works better than methotrexate. Laboratory studies have
shown that pralatrexate works better than methotrexate at killing cancer cells.
Pralatrexate has already been studied in patients with other types of cancers, such as
lymphoma and lung cancer. The results from those studies were promising. Pralatrexate was
recently approved by the Food and Drug Administration (FDA) as a new treatment for a cancer
called peripheral T cell lymphoma.
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder [Recruiting]
The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and
folic acid, is effective in the treatment of advanced or metastatic bladder cancer. The
study will also investigate the safety of pralatrexate with vitamin B12 and folic acid in
this patient population. Additionally, this study includes the collection of blood samples
to investigate the pharmacokinetics (PK) of pralatrexate in this patient population (PK is
the activity of a drug in the body over a period of time, including how the drug is
absorbed, distributed in the body, localized in the tissues, and excreted from the body).
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [Recruiting]
The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and
folic acid, is effective in the treatment of relapsed or refractory B-cell Non-Hodgkin's
lymphoma (NHL). The study will also investigate the safety of pralatrexate with vitamin B12
and folic acid in this patient population. Additionally, this study includes the collection
of blood samples to investigate the pharmacokinetics (PK) of pralatrexate in this patient
population (PK is the activity of a drug in the body over a period of time, including how
the drug is absorbed, distributed in the body, localized in the tissues, and excreted from
Reports of Suspected Folotyn (Pralatrexate) Side Effects
Febrile Neutropenia (5),
Mucosal Inflammation (5),
Disease Progression (4),
Platelet Count Increased (3),
Device Related Infection (3),
Abdominal Pain Upper (3),
Acute Respiratory Distress Syndrome (3),
Stomatitis (3), more >>